Cytogen
Executive Summary
Additional dose ranging studies of between 0.2 and 2.0 milligrams of the cancer imaging agent OncoScint are under way and, upon successful completion, will be followed by expanded trials in colorectal cancer patients, Cytogen reports. FDA asked for the additional studies at a mid-August meeting ("The Pink Sheet" Sept. 5, T&G-5)....
|
Additional dose ranging studies of between 0.2 and 2.0 milligrams
of the cancer imaging agent
OncoScint
are under way
and, upon successful completion, will be followed by expanded
trials in colorectal cancer patients, Cytogen reports. FDA asked
for the additional studies at a mid-August meeting ("The Pink
Sheet" Sept. 5, T&G-5).... |